Cargando…

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877867/ https://www.ncbi.nlm.nih.gov/pubmed/29630065 http://dx.doi.org/10.2147/CMAR.S165745

Ejemplares similares

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study
por: Restelli, Umberto, et al.
Publicado: (2017)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
Publicado: (2019)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]
Publicado: (2021)

Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer
Publicado: (2023)

Humanistic and economic burden of fibromyalgia in Japan [Corrigendum]
Publicado: (2016)

Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”
por: Saltus, Catherine W., et al.
Publicado: (2019)

Corrigendum to: The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program
Publicado: (2020)

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
Publicado: (2015)

Corrigendum to “GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)”
Publicado: (2022)

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
por: Dragomir, Alice, et al.
Publicado: (2014)

The Economic Burden of Metastatic Castration Resistant Prostate Cancer and Skeletal Related Events in Japanese University Hospitals
por: Satoh, Takefumi, et al.
Publicado: (2018)

Corrigendum to ‘An estimate of the economic burden of venous leg ulcers associated with deep venous disease’
Publicado: (2021)

Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”
por: Masson, Susan, et al.
Publicado: (2016)

Corrigendum for “Adverse Outcomes and Economic Burden of Congenital Adrenal Hyperplasia Late Diagnosis in the Newborn Screening Absence”
Publicado: (2021)

The economic burden of obesity in Italy: a cost-of-illness study
por: d’Errico, Margherita, et al.
Publicado: (2021)

PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
por: Pu, Jun, et al.
Publicado: (2022)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
por: Pollard, Matthew E., et al.
Publicado: (2017)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women [Corrigendum]
Publicado: (2017)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
Publicado: (2019)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis
por: Marcellusi, Andrea, et al.
Publicado: (2018)

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992–2003
por: Clarke, N.W., et al.
Publicado: (2020)

Combination of phospholipase Cε knockdown with GANT61 sensitizes castration-resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway
por: Sun, Wei, et al.
Publicado: (2022)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

Clinical and economic studies of eptifibatide in coronary stenting [Corrigendum]
Publicado: (2014)

COPD management costs according to the frequency of COPD exacerbations in UK primary care [Corrigendum]
Publicado: (2014)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
Publicado: (2015)

Corrigendum to Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
Publicado: (2019)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Subcellular Organelle-Targeted Nanostructured Lipid Carriers for the Treatment of Metastatic Breast Cancer [Corrigendum]
Publicado: (2023)

Perinatal mental health around the world: priorities for research and service development in Italy – CORRIGENDUM
por: Grussu, Pietro, et al.
Publicado: (2022)

Family Wellbeing and Sexual Health of Patients Receiving Treatment for Prostate Cancer [Corrigendum]
Publicado: (2023)

Corrigendum to “Somatostatin Negatively Regulates Parasite Burden and Granulomatous Responses in Cysticercosis”
por: Khumbatta, Mitra, et al.
Publicado: (2015)

Sinonasal Symptoms in COPD: Burden and Associations with Clinical Markers of Disease [Corrigendum]
Publicado: (2022)

Corrigendum to “Self-isolation” [J. Math. Econom. 93 (2021) 102483]
por: Baril-Tremblay, Dominique, et al.
Publicado: (2022)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v9dohfeu40jo15ntp8sjdack41